|
|
|
|
|
市場調査レポート
特殊医薬品：未開分野での成功のためのガイド
Specialty Pharma: Guide to Success at the New Frontier
|
当商品の販売は、2011年12月21日を持ちまして終了しました。
Abstract
Introduction
Recently catapulted into the pharmaceutical industry limelight, Specialty
Pharma may well be the solution to many of Big Pharma' s current woes. Its
success driven largely by astute manipulation of the business and market
issues that currently plague Big Pharma, Specialty Pharma has shown the
potential to capture and fi rmly command market spaces once dominated by Big
Pharma.
Get the Answers You Need to Shape Your Strategy
- The emergence of Specialty Pharma as a market force occurred as Big Pharma
and Mid Pharma began to consolidate. What strategies will Specialty Pharma
pursue as it continues to capitalize on Big Pharma' s looming market
problems?
- Patents have become a trapdoor for both Big Pharma and Mid Pharma alike;
once patents expire, these companies fi nd themselves hanging in a market
abyss. What methods are Specialty Pharma using to sidestep such patent expiry
pitfalls? What specifi c markets or patient cohorts are receiving attention
from Specialty Pharma?
- Value-for-money is the mantra of today' s knowledgeable and organized
health care customers-a challenge for Specialty Pharma, which has received
condemnation over its pricing of orphan drugs. How can Specialty Pharma
best present its pricing practices to an increasingly informed and skeptical
consumer audience?
Scope
- Market drivers: business factors and issues that are driving the
transformation of the pharma market.
- Market overview: market conditions that contributed to the emergence and
subsequent growth of Specialty Pharma.
- Success and uncertainty: how Specialty Pharma' s success has altered its
market space, and how these companies need to respond to the changing
marketplace.
- Specialty Pharma business models: 11 business models, with examples of
companies that utilize them.
- Challenges: threats to the continued growth of the Specialty Pharma sector.
- Market outlook: opportunities and strategies for Specialty Pharma
companies to succeed in today' s changing pharma business environment.
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- An Aspirational Business Model
- Transformational Drivers
- Paucity of New Products
- Parsimony of Customers
- Pharma' s Aversion to Risk
- R&D Polarization
- Lure and Trap of Patents
- Misreading the Runes
- The Rise of Specialty Pharma
- The Price of Success
- Dealing with Uncertainty
- New Specialty Business Models
- Product Acquisition
- Spin-Offs
- Company Acquisition
- Research & Development
- Specialty Generics
- Drug Delivery and Formulation
- Geographic Specialization
- Therapy Area Specialization
- Customer Specialization
- Unmet Medical Need Specialization
- Orphan Drugs
- Challenges
- Niche-Buster Strategies
- Theranostics
- Value for Money
- The Three Cs: Crowded, Concentrated, and Competitive
- A Specialty Pharma Guide to Success
- Multivectored Business Models
- Lean Structures
- Enhanced Customer Focus
- Real Differentiation
- Value-for-Money
- Greater Acceptance of Risk
- Professionalism
- Capturing the Future
Figures
- 1. Big Pharma, Specialty Pharma, and Biotech-Year-end Market Value, 2006
- 2. Research and Development Expenses, Total NDAs, and NDAs for NME
Submissions, 1993-2004
- 3. Pharma Industry Profi ts from the Developed World, 2006
- 4. Specialty Pharma Forced to Reconfi gure its Business Model
- 5. Specialty Pharma Now Utilizes a Range of Business Models
- 6. Specialty Pharma' s Multivectored Business Models
- 7. Specialty Pharma Needs a Holistic Approach to Differentiation to Create
New Value Perceptions
Tables
- 1. Select Specialty Pharma Companies and Key Drugs-2006 Worldwide Sales
|
 |
